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Abstract		Background:	Information	on	influenza-associated	mortality	in	Russia	is	limited.		Methods:	Using	previously	developed	methodology	(Goldstein	et	al.,	Epidemiology	2012),	we	regressed	the	monthly	rates	of	mortality	for	respiratory	causes,	as	well	as	circulatory	causes	linearly	against	the	monthly	proxies	for	the	incidence	of	influenza	A/H3N2,	A/H1N1	and	B	(obtained	using	data	from	the	Smorodintsev	Research	Institute	of	Influenza	(RII)),	adjusting	for	the	baseline	rates	of	mortality	not	associated	with	influenza	circulation	and	temporal	trends.		Results:	For	the	2013/14	through	the	2018/19	seasons,	influenza	circulation	was	associated	with	an	average	annual	17636	(95%	CI	(9482,25790))	deaths	for	circulatory	causes	and	4179	(3250,5109)	deaths	for	respiratory	causes,	with	the	largest	number	of	deaths	(32298	(18071,46525)	for	circulatory	causes	and	6689	(5019,8359)	for	respiratory	causes)	estimated	during	the	2014/15	influenza	season.	The	biggest	contributor	to	both	circulatory	and	respiratory	influenza-associated	deaths	was	influenza	A/H3N2,	followed	by	influenza	B	and	A/H1N1.	Compared	to	the	2013/14	through	the	2015/16	seasons,	during	the	2016/17	through	the	2018/19	seasons	(when	levels	of	influenza	vaccination	were	significantly	higher),	the	volume	of	influenza-associated	mortality	declined	by	about	16.1%,	or	3809	annual	respiratory	and	circulatory	deaths.	
	Conclusions:	Influenza	circulation	is	associated	with	a	substantial	mortality	burden	in	Russia,	particularly	for	circulatory	deaths,	with	some	reduction	observed	following	the	major	increase	in	vaccination	coverage.	Those	results	support	the	potential	utility	of	further	extending	the	levels	of	influenza	vaccination,	the	use	of	quadrivalent	influenza	vaccines,	and	extra	efforts	for	protecting	individuals	with	circulatory	disease	in	Russia,	including	vaccination	and	the	use	of	antiviral	medications.			
Introduction	
	Annual	epidemics	associated	with	the	circulation	of	influenza	A/H3N2,	A/H1N1	and	B	take	place	in	Russia	[1,2].	Such	epidemics	are	known	to	result	in	a	substantial	toll	of	mortality	in	other	countries	in	the	Northern	Hemisphere,	e.g.	[3-9],	including	mortality	for	circulatory	causes	[3,4],	with	influenza	additionally	known	to	be	associated	with	a	variety	of	cardiovascular	manifestations	[10,11].	At	the	same	time,	there	is	limited	information	on	the	burden	of	influenza-associated	mortality	in	Russia.	Such	information	is	largely	related	to	deaths	with	influenza	in	the	diagnosis,	e.g.	[2,12-15].	However,	cases	with	influenza	in	the	diagnosis	are	known	to	represent	only	a	small	fraction	of	all	influenza-associated	deaths.	For	example,	it	was	found	in	[11]	that	laboratory-confirmed	influenza	infection	increases	the	risk	of	an	acute	myocardial	infarction	by	a	factor	of	about	6.	However,	influenza	infection	is	detected/diagnosed	extremely	rarely	for	such	excess	myocardial	infarctions	and	associated	deaths.	Additionally,	cases	with	influenza	in	the	diagnosis	may	not	be	representative	of	the	relative	contribution	of	the	major	influenza	(sub)types	(A/H3N2,	A/H1N1	and	B)	to	mortality.	Indeed,	the	age	distribution	of	diagnosed	deaths	with	influenza	A/H1N1	is	significantly	younger	compared	to	diagnosed	deaths	with	influenza	A/H3N2	and	B	in	Russia,	e.g.	[13].	This	suggests	that	deaths	associated	with	A/H1N1	infections	are	much	more	likely	to	be	diagnosed	compared	to	deaths	associated	with	A/H3N2	and	influenza	B	infections.	Indeed,	even	during	the	2014/15	season	when	influenza	A/H1N1	circulation	was	minimal,	influenza	A/H1N1	was	found	to	represent	the	largest	contribution	to	diagnosed	influenza-related	deaths	in	Russia	[14,15].	All	of	this	
suggests	that	better	understanding	is	needed	of	the	overall	volume	of	influenza-related	deaths	in	Russia,	as	well	as	of	the	relative	contribution	of	each	of	the	major	influenza	(sub)types	to	mortality,	including	changes	in	the	above	following	the	significant	increase	in	influenza	vaccination	coverage	starting	the	2015/16	season.		In	our	earlier	work	[3,4,16],	we	introduced	a	new	method	for	estimating	the	burden	of	severe	outcomes	associated	with	influenza	and	the	respiratory	syncytial	virus	(RSV),	designed	to	address	several	limitations	of	some	of	the	previously	employed	inference	models.	An	important	feature	of	that	approach	is	the	use	of	RSV	and	influenza	A/H3N2,	A/H1N1,	and	B	incidence	proxies	that	are	expected	to	be	linearly	related	to	the	population	incidence	of	those	viruses;	such	proxies	for	influenza	(sub)types	combine	data	on	medical	consultations	for	influenza-like	illness	(ILI)	with	data	on	the	testing	of	respiratory	specimens	from	symptomatic	individuals	[3,4,16].	We’ve	applied	those	incidence	proxies	to	estimate	the	rates	of	influenza-associated	mortality	stratified	by	age/cause	of	death	in	the	US	[3,4],	with	the	corresponding	method	being	later	adopted	for	the	estimation	of	influenza-associated	mortality	in	other	countries	as	well,	e.g.	[6-9].	In	this	paper,	we	derive	the	analogous	proxies	for	the	weekly/monthly	incidence	of	influenza	A/H3N2,	A/H1N1,	and	B	in	Russia	based	on	the	surveillance	data	from	the	Smorodintsev	Research	Institute	of	Influenza	(RII)	[17,18]	that	includes	information	on	medical	consultations	for	influenza/ARI	symptoms,	data	on	testing	of	respiratory	specimensfor	the	different	influenza	(sub)types,	as	well	as	data	on	the	antigenic	characterization	of	the	circulating	influenza	strains.	We	then	apply	the	inference	model	from	[3,4,16]	to	relate	those	incidence	proxies	to	the	monthly	data	from	the	Russian	Federal	State	Statistics	Service	(Rosstat)	[19,20]	on	the	rates	of	death	for	respiratory	causes	and	circulatory	causes	to	estimate	the	corresponding	mortality	rates	associated	with	the	circulation	of	the	major	influenza	(sub)types	during	the	2013/14	through	the	2018/19	influenza	seasons	in	Russia.			
Methods		
Data	
Monthly	data	on	mortality	for	respiratory	and	circulatory	causes	of	in	Russia	were	obtained	from	[19].	Monthly	mortality	counts	for	respiratory	and	circulatory	deaths	were	then	converted	to	monthly	rates	of	mortality	for	those	causes	per	100,000	individuals	using	population	data	from	Rosstat	[20].	Influenza	is	known	to	be	associated	with	mortality	for	other	causes	as	well,	including	neoplasms	and	metabolic	diseases	[3,4];	however	finer	(e.g.	weekly)	mortality	data	are	needed	to	ascertain	the	signals	from	influenza	circulation	in	the	corresponding	time	series.			Weekly	data	on	the	rates	of	ILI/ARI	consultation	per	10,000	individuals	in	Russia	are	available	from	[17]	(where	they	are	called	the	influenza/ARI	rates).	Data	on	the	weekly	percent	of	respiratory	specimens	from	symptomatic	individuals	that	were	RT-PCR	positive	for	influenza	A/H1N1,	A/H3N2	and	influenza	B	are	available	from	[18].		
Incidence	proxies	Only	a	fraction	of	individuals	presenting	with	influenza/ARI	symptoms	are	infected	with	influenza.	We	multiplied	the	weekly	rates	of	influenza/ARI	consultation	per	10,000	individuals	[17]	by	the	weekly	percentages	of	respiratory	specimens	from	symptomatic	individuals	that	were	RT-PCR	positive	for	each	of	influenza	A/H1N1,	A/H3N2	and	B	[18]	to	estimate	the	weekly	incidence	proxies	for	each	of	the	corresponding	influenza	(sub)types:			
Weekly	influenza	(sub)type	incidence	proxy	=																																													(1)	
=	Rate	of	consultations	for	influenza/ARI	*	%	All	respiratory	specimens	that	were	positive	for	
the	(sub)type		As	noted	in	[3],	those	proxies	are	expected	to	be	proportional	to	the	weekly	population	incidence	for	the	each	of	the	major	influenza	(sub)types	(hence	the	name	“proxy”).	Monthly	incidence	proxies	for	influenza	A/H1N1,	A/H3N2	and	B	were	obtained	as	the	weighted	average	of	the	weekly	incidence	proxies	for	those	weeks	that	overlapped	with	a	given	month;	specifically,	for	each	influenza	(sub)type	and	month,	the	incidence	proxy	for	each	week	was	multiplied	by	the	number	of	days	in	that	week	that	were	part	of	the	
corresponding	month	(e.g.	7	if	the	week	was	entirely	within	that	month),	then	the	results	were	summed	over	the	different	weeks	and	divided	by	the	number	of	days	in	the	corresponding	month.	To	relate	the	incidence	proxies	for	the	major	influenza	(sub)types	to	monthly	mortality	rates	we	first	shift	the	incidence	proxies	by	one	week	forward	to	accommodate	for	the	delay	between	infection	and	death	[3,4],	then	use	the	shifted	weekly	incidence	proxies	to	obtain	the	corresponding	monthly	incidence	proxies	as	above.			The	relation	between	an	incidence	proxy	and	the	associated	mortality	may	change	over	time.	In	particular,	influenza	B	is	characterized	by	the	circulation	of	B/Yamagata	and	
B/Victoria	viruses.	It	is	known	that	the	age	distribution	for	the	B/Yamagata	infections	is	notably	older	than	for	the	B/Victoria	infections	[21,22].	Correspondingly,	the	relation	between	the	incidence	proxy	(which	reflects	influenza	incidence	in	the	general	population)	and	influenza-related	mortality	(which	for	influenza	B	largely	reflects	mortality	in	older	individuals)	may	be	quite	different	for	influenza	B/Yamagata	compared	to	influenza	
B/Victoria.	Influenza	B/Yamagata	dominated	the	influenza	B	circulation	in	Russia	during	the	2013/14,	2014/15,	2017/18	and	the	2018/19	seasons,	while	influenza	B/Victoria	was	dominant	during	the	2015/16	and	the	2016/17	seasons	[18].	Correspondingly,	we	split	the	incidence	proxy	for	influenza	B	into	two:	one	for	the	2013/14,	2014/15,	2017/18	and	the	2018/19	seasons	(called	the	B/Yamagata	proxy),	and	one	for	the	2015/16	and	the	2016/17	seasons	(called	the	B/Victoria	proxy).	During	the	2014/15	and	the	2015/16	influenza	seasons,	a	drift	variant	of	influenza	A/H3N2	with	reduced	titers	to	the	vaccine-type	strains	circulated	in	Russia	[18];	moreover	this	variant	was	known	to	cause	high	levels	of	mortality	in	other	countries	[7].	During	the	other	four	seasons	in	our	study,	the	circulating	A/H3N2	strains	were	similar	to	the	vaccine-type	strains.	Correspondingly,	we	split	the	A/H3N2	incidence	proxy	into	two:	one	for	the	2014/15	and	the	2015/16	seasons	(called	the	drift	A/H3N2	proxy),	and	one	for	the	2013/14,	2106/17,	2017/18	and	the	2018/19	season	(called	the	matching	A/H3N2	proxy).	Finally,	we	know	that	for	all	six	influenza	seasons	in	the	data,	the	majority	of	circulating	influenza	A/H1N1	viruses	were	similar	to	the	vaccine-type	viruses	during	the	corresponding	seasons.	Figure	1	plots	the	monthly	incidence	proxies	for	influenza	A/H1N1,	A/H3N2	and	B	in	Russia	between	
07/2013	and	07/2019	(73	months),	with	the	proxies	for	influenza	A/H3N2	and	B	further	split	into	two	as	described	in	this	paragraph.		
Inference	method	If	𝑀(𝑡)	is	the	mortality	rate	for	a	given	cause	on	month	𝑡 	(with	𝑡 = 1	for	07/2013),	and	𝐴/𝐻3𝑁2!"#$!(𝑡),𝐴/𝐻3𝑁2!"#$%(𝑡),𝐴/𝐻1𝑁1(𝑡),𝐵/𝑉𝑖𝑐𝑡𝑜𝑟𝑖𝑎(𝑡),𝐵/𝑌𝑎𝑚𝑎𝑔𝑎𝑡𝑎(𝑡)	are	the	incidence	proxies	for	the	different	influenza	(sub)types	on	month	𝑡	as	described	in	the	previous	subsection,	then	the	inference	model	in	[3,4]	suggests	that				𝑀 𝑡 = 𝛽! + 𝛽! ∙ 𝐴/𝐻3𝑁2!"#$!(𝑡)+ 𝛽! ∙ 𝐴/𝐻3𝑁2!"#$%(𝑡)+ 𝛽! ∙ 𝐴/𝐻1𝑁1(𝑡)+ 𝛽! ∙𝐵/𝑉𝑖𝑐𝑡𝑜𝑟𝑖𝑎(𝑡)+ 𝛽! ∙  𝐵/𝑌𝑎𝑚𝑎𝑔𝑎𝑡𝑎(𝑡)+ 𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒 + 𝑇𝑟𝑒𝑛𝑑 +  𝑁𝑜𝑖𝑠𝑒																(2)	
	Here	𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒	is	the	baseline	rate	of	mortality	not	associated	with	influenza	circulation	that	is	periodic	with	yearly	periodicity.	We	will	model	it	as		 𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑡 = 𝛽! ∙ cos 2𝜋𝑡12 + 𝛽! ∙ sin 2𝜋𝑡12  + 𝛽! ∙ Jan(t)		Here	𝐽𝑎𝑛	is	a	variable	equaling	1	for	the	month	of	January,	0	otherwise.	The	reason	for	including	this	variable	is	that	the	monthly	(rather	than	annual)	mortality	data	in	[19]	is	operational,	with	some	of	the	mortality	not	registered	during	a	given	calendar	year	being	added	to	January	on	the	next	year	[23].	Furthermore,	the	January	effect	(likely	weather-related)	on	circulatory	mortality	in	Russia	was	established	in	[24].	The	(temporal)	trend	is	modeled	as	a	cubic	polynomial	in	time	(month).	Finally,	the	sensitivity	of	the	estimates	of	the	contribution	of	influenza	to	mortality	with	regard	to	the	model	for	the	baseline	is	discussed	in	the	Supporting	Information	for	[3]	(where	limited	sensitivity	was	found).		The	Akaike	Information	Criterion	(AIC)	is	adopted	to	select	the	variables	(covariates)	in	the	model	in	eq.	2	for	each	mortality	cause,	with	the	variable	whose	omission	results	in	the	largest	decline	in	the	AIC	score	being	dropped	at	each	step	until	no	omissions	of	a	variable	
decrease	the	AIC	score.	The	model	equations	for	respiratory	mortality	and	circulatory	mortality	selected	by	the	stepwise	AIC	criterion	are	as	follows:		
Respiratory	mortality	𝑀!"#$ 𝑡 = 𝛽! + 𝛽! ∙ 𝐴/𝐻3𝑁2!"#$!(𝑡)+ 𝛽! ∙ 𝐴/𝐻3𝑁2!"#$%(𝑡)+ 𝛽! ∙ 𝐴/𝐻1𝑁1(𝑡)+ 𝛽! ∙ 𝐵/𝑌𝑎𝑚𝑎𝑔𝑎𝑡𝑎(𝑡)+ 𝛽! ∙ sin !!"!"  + 𝛽! ∙ Jan(t)+ 𝛽! ∙ t+ 𝛽! ∙ 𝑡! + 𝛽! ∙ 𝑡!														(3)	
	
Circulatory	mortality		𝑀!"#!  𝑡 = 𝛽! + 𝛽! ∙ 𝐴/𝐻3𝑁2!"#$!(𝑡)+ 𝛽! ∙ 𝐴/𝐻3𝑁2!"#$%(𝑡)+ 𝛽! ∙ 𝐴/𝐻1𝑁1(𝑡)+ 𝛽! ∙ 𝐵/𝑌𝑎𝑚𝑎𝑔𝑎𝑡𝑎(𝑡)+ 𝛽! ∙ sin !!"!"  + 𝛽! ∙ Jan(t)+ 𝛽! ∙ t+ 𝛽! ∙ 𝑡!																																(4)		We	note	that	the	𝐵/𝑉𝑖𝑐𝑡𝑜𝑟𝑖𝑎	incidence	proxy	is	not	selected	by	the	AIC	for	either	model,	whereas	the	other	four	incidence	proxies	are	all	present	in	each	model.	
	
	
Results	
	Figure	1	plots	the	monthly	incidence	proxies	for	influenza	A/H1N1,	A/H3N2	(both	matching	and	drifted)	and	B	(both	Victoria	and	Yamagata)	in	Russia	between	07/2013	and	07/2019.	Figure	2	plots	the	daily	rates	of	respiratory	deaths	and	circulatory	deaths	by	month	between	07/2013	and	07/2019.	We	note	that	there	is	a	good	temporal	correspondence	between	the	“bumps”	in	mortality	rates	and	peaks	of	influenza	circulation,	save	for	the	sizeable	wave	of	influenza	B/Victoria	in	2017.	The	lack	of	the	corresponding	visual	effect	of	influenza	B/Victoria	circulation	on	mortality	may	be	related	to	the	young	age	distribution	for	influenza	B/Victoria	infections	(Methods;	[21,22]).		
	
	
	
Figure1:	Monthly	incidence	proxies	for	influenza	A/H3N2,	A/H1N1	and	B	in	Russia,	07/2013	through	07/2019.			
	
	
Figure	2:	Rates	of	daily	mortality	for	respiratory	causes	(per	one	million	individuals	in	Russia)	and	circulatory	causes	(per	100,000	individuals)	by	month,	07/2013	through	07/2019.		Figure	3	plots	the	fits	for	the	model	for	respiratory	mortality	given	by	eq.	3.	Figure	4	plots	the	fits	for	the	model	for	circulatory	mortality	given	by	eq.	4.	The	fits	appear	to	be	fairly	temporally	consistent,	particularly	for	respiratory	deaths,	with	the	weekly	contribution	of	influenza	to	mortality	estimated	as	the	difference	between	the	red	and	the	green	curves	in	Figures	3	and	4.	Those	fits	help	support	the	basic	structure	of	our	model,	namely	that	monthly	rates	of	both	respiratory	and	circulatory	mortality	in	Russia	are	largely	explained	by	influenza’s	contribution	to	the	regular	pattern	mortality	(baseline	+	trend).	
		
	
Figure	3:	Model	fit	for	the	daily	rates	of	respiratory	deaths	per	100,000	by	month	in	Russia,	07/2013	though	07/2109.	The	contribution	of	influenza	to	respiratory	mortality	is	represented	by	the	difference	between	the	red	and	the	green	curves.		
		
Figure	4:	Model	fit	for	the	daily	rates	of	circulatory	deaths	per	100,000	by	month	in	Russia,	07/2013	though	07/2109.	The	contribution	of	influenza	to	circulatory	mortality	is	represented	by	the	difference	between	the	red	and	the	green	curves.		Table	1	presents	the	estimates	of	the	annual	contribution	of	influenza	to	circulatory	and	respiratory	mortality	for	each	of	the	2013/14	through	the	2018/19	seasons	(with	each	influenza	season	assumed	to	run	from	September	through	June),	as	well	as	the	annual	averages	for	the	corresponding	contributions	for	that	time	period	(6	seasons).	We	estimate	an	average	annual	17636	(95%	CI	(9482,25790))	deaths	for	circulatory	causes	and	4179	(3250,5109)	deaths	for	respiratory	causes	during	our	study	period.	The	largest	number	of	both	circulatory	and	respiratory	deaths	was	estimated	during	the	2014/15	seasons	when	
drift	variants	of	both	influenza	A/H3N2	and	influenza	B/Yamagata	circulated	in	Russia	[18].	We	note	that	this	season	was	also	associated	with	high	rates	of	mortality	in	certain	other	countries,	e.g.	[7].	We	also	note	that	the	levels	of	influenza	vaccination	in	Russia	rose		significantly	starting	the	2016/17	season.	Compared	to	the	2013/14	through	the	2015/16	seasons	(first	3	seasons),	during	the	2016/17	through	the	2018/19	seasons,	the	volume	of	influenza-associated	mortality	declined	by	about	16.1%,	or	3809	annual	deaths.	Finally,	we	note	that	the	estimated	ratio	of	circulatory	to	respiratory	influenza-associated	deaths	in	Russia	(about	4.22-to-1,	Table	1)	is	quite	higher	that	the	corresponding	estimate	(about	1.35-to-1,	[3])	for	the	US.	At	the	same	time,	the	overall	ratio	of	circulatory-to-respiratory	deaths	in	Russia	(about	14-to-1	in	2018,	[20])	is	much	higher	than	the	corresponding	ratio	in	the	US	(about	3.08-to-1	in	2017,	[25]).		 Season	 Circulatory	causes	 Respiratory	causes	2013/14	 12364	(5497,19230)	 3116	(2329,3902)	2014/15	 32298	(18071,46525)	 6689	(5019,8359)	2015/16	 13128	(1046,25211)	 3565	(2171,4959)	2016/17	 17462	(4376,30548)	 3540	(2045,5035)	2017/18	 17463	(6294,28632)	 4887	(3606,6167)	2018/19	 13101	(4760,21442)	 3280	(2330,4229)	Annual	average	 17636	(9482,25790)	 4179	(3250,5109)		
Table	1:	Annual	and	average	annual	number	of	influenza-associated	circulatory	and	respiratory	deaths	(with	95%	confidence	intervals)	for	the	2013/14	through	the	2018/19	influenza	seasons	in	Russia.		Table	2	estimates	the	average	annual	number	of	circulatory	and	respiratory	deaths	for	the	2013/14	through	the	2018/19	seasons	associated	with	the	circulation	of	influenza	A/H2N2,	A/H1N1	and	B.	We	estimate	that	during	our	study	period,	influenza	A/H3N2	was	responsible	for	51.8%	of	all	circulatory	influenza-associated	deaths	and	37.2%	of	all	respiratory	influenza-associated	deaths	(Table	2	vs.	Table	1);	influenza	A/H1N1	was	
responsible	for	23.4%	of	all	circulatory	influenza-associated	deaths	and	29.5%	of	all	respiratory	influenza-associated	deaths;	influenza	B	was	responsible	for	24.9%	of	all	circulatory	influenza-associated	deaths	and	33.3%	of	all	respiratory	influenza-associated	deaths.		 Influenza	(sub)type	 Circulatory	deaths	 Respiratory	deaths	A/H3N2	 9140	(2608,15672)	 1553	(805,2301)	A/H1N1	 4100	(-156,8355)	 1233	(746,1721)	B	 4396	(-760,9553)	 1393	(799,1987)		
Table	2:	Average	annual	number	of	circulatory	and	respiratory	deaths	associated	with	the	circulation	of	influenza	A/H3N2,	A/H1N1	and	B	during	the	2013/14	through	the	2018/19	seasons.			
Discussion	
	Influenza	circulation	is	known	to	be	associated	with	a	substantial	mortality	burden	in	the	Northern	Hemisphere,	e.g.	[3-9].	At	the	same	time,	there	is	limited	information	on	the	volume	of	influenza-related	mortality	in	Russia,	with	estimates	based	on	deaths	with	influenza	in	the	diagnosis	[2,12-15]	representing	only	a	small	fraction	of	all	influenza-associated	deaths	and	not	allowing	for	the	evaluation	of	the	relative	contribution	of	different	influenza	subtypes	to	the	full	volume	of	influenza-associated	mortality	(Introduction).		In	this	paper,	we	applied	the	previously	developed	methodology	that	was	used	to	evaluate	the	rates	of	influenza-associated	mortality	in	several	countries,	e.g.	[3,4,6-9]	to	estimate	the	rates	of	influenza-associated	mortality	for	circulatory	causes	and	respiratory	causes	in	Russia	during	the	2013/14	through	the	2018/19	influenza	seasons.	We	estimate	an	average	annual	17636	(95%	CI	(9482,25790))	circulatory	death	and	4179	(3250,5109)	respiratory	deaths	during	our	study	period.	We	note	that	the	high	rates	of	circulatory	influenza-associated	deaths	are	consistent	with	the	high	burden	of	circulatory	
mortality	in	Russia	[20],	as	well	as	the	evidence	about	the	cardiovascular	manifestations	of	influenza	infection	[10,11].	Influenza	A/H3N2	was	the	largest	contributor	to	each	cause	of	death,	with	influenza	A/H1N1	and	B	(mostly	B/Yamagata,	which	is	consistent	with	some	evidence	from	other	countries	[26,21,22])	also	making	a	sizeable	contribution	to	the	volume	of	influenza-associated	mortality.	Additionally,	the	significant	increase	in	the	influenza	vaccination	levels	in	Russia	starting	the	2016/17	season	was	associated	with	some	reduction	(16.1%	on	average)	in	the	annual	volume	of	influenza-associated	mortality.	We	hope	that	this	work	may	help	inform	mitigation	efforts.	In	particular,	our	findings	support	further	increases	in	vaccination	coverage,	particularly	for	individuals	with	circulatory	disease,	with	the	contribution	of	influenza	B/Yamagata	to	mortality	(particularly	during	seasons	for	which	there	was	a	mismatch	between	the	circulating	influenza	B	viruses	and	the	virus	recommended	for	the	trivalent	vaccine	[18])	also	supporting	the	use	of	quadrivalent	vaccines.	We	also	note	in	that	regard	that	the	2018/19	influenza	season	saw	minimal	circulation	of	influenza	B	in	Russia	[17],	raising	the	possibility	of	a	major	influenza	B	epidemic	during	the	2019/20	season;	as	influenza	
B/Yamagata	strains	are	not	present	in	the	trivalent	vaccine	recommended	for	the	2019/20	season	[27],	this	further	supports	the	need	for	a	quadrivalent	influenza	vaccine,	particularly	for	individuals	with	cardiac	disease.	Additionally,	administration	of	antiviral	medications	for	certain	population	subgroups	defined	by	age	and	presence	of	underlying	health	conditions	(particularly	circulatory	diseases)	may	help	mitigate	the	burden	of	severe	outcomes	during	influenza	epidemics	in	Russia.		Our	paper	has	some	limitations.	We	only	had	access	to	monthly	mortality	data;	moreover,	those	data	are	operational,	with	some	delays	in	reporting,	and	some	unreported	deaths	during	a	given	calendar	year	being	reported	for	January	of	the	next	year	[23].	Finer	mortality	data	stratified	by	week/age	group	are	needed	to	get	a	more	comprehensive	understanding	of	the	contribution	of	influenza	to	mortality	for	different	causes	of	death	in	Russia.	Additionally,	due	to	the	relatively	small	number	of	data	points	in	the	regression	framework	adopted	in	this	paper,	we	used	a	simple	trigonometric	model	for	the	baseline	rates	of	mortality	not	associated	with	influenza	circulation.	Previous	work	(e.g.	Supporting	
Information	for	[3])	suggests	limited	sensitivity	of	the	estimates	of	the	rates	of	influenza-associated	mortality	on	the	model	for	the	baseline	rates	of	non-influenza	mortality.		We	believe	that	despite	those	limitations,	this	work	provides	a	national	study	of	influenza-related	mortality	in	Russia,	giving	evidence	for	the	substantial	burden	of	influenza-associated	mortality,	particularly	for	circulatory	causes,	delineating	the	contribution	of	different	influenza	(sub)types	to	mortality	and	suggesting	likely	effects	of	the	recent	increases	in	vaccination	coverage	on	the	volume	of	influenza-associated	mortality.	In	particular,	our	work	supports	further	increases	in	vaccination	coverage	levels,	particularly	for	individuals	with	circulatory	disease,	as	well	as	the	use	of	quadrivalent	influenza	vaccines	and	of	antiviral	medications	for	certain	population	groups.	We	hope	that	this	work	would	stimulate	further	efforts	involving	more	granular	data	(in	particular,	weekly	mortality	data,	as	well	as	data	stratified	by	age)	to	better	understand	the	effect	of	influenza	epidemics	in	Russia	on	mortality	and	help	inform	mitigation	efforts	for	different	population	subgroups.			
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